293 related articles for article (PubMed ID: 23710205)
1. New insights in recurrent HCV infection after liver transplantation.
Hsu SH; Yeh ML; Wang SN
Clin Dev Immunol; 2013; 2013():890517. PubMed ID: 23710205
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
[TBL] [Abstract][Full Text] [Related]
3. [Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
Park JI; Choi KM; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Chung YH; Lee YS; Suh DJ
Korean J Hepatol; 2007 Dec; 13(4):543-55. PubMed ID: 18159152
[TBL] [Abstract][Full Text] [Related]
4. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
5. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
6. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
Fontana RJ; Hughes EA; Appelman H; Hindes R; Dimitrova D; Bifano M
Liver Transpl; 2012 Sep; 18(9):1053-9. PubMed ID: 22706796
[TBL] [Abstract][Full Text] [Related]
7. Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report.
Pellicelli AM; Morrone A; Barbieri L; Andreoli A
Ann Hepatol; 2012; 11(6):951-4. PubMed ID: 23109461
[TBL] [Abstract][Full Text] [Related]
8. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
[TBL] [Abstract][Full Text] [Related]
9. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.
Coilly A; Furlan V; Roche B; Barau C; Noël C; Bonhomme-Faivre L; Antonini TM; Roque-Afonso AM; Samuel D; Taburet AM; Duclos-Vallée JC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5728-34. PubMed ID: 22908172
[TBL] [Abstract][Full Text] [Related]
10. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient.
Montalbano M; Pasulo L; Sonzogni A; Remuzzi G; Colledan M; Strazzabosco M
J Clin Gastroenterol; 2007 Feb; 41(2):216-20. PubMed ID: 17245223
[TBL] [Abstract][Full Text] [Related]
11. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder.
Al Nahdi N; Ford JA; Greanya ED; Harrigan JA; Tse I; Steinbrecher UP; Erb SR; Yoshida EM
Ann Hepatol; 2013; 12(1):156-60. PubMed ID: 23293209
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of hepatitis C virus disease after living donor liver transplantation: relationship with in situ hybridisation data.
Masuda Y; Nakazawa Y; Matsuda K; Sano K; Mita A; Ohno Y; Urata K; Ikegami T; Miwa S; Miyagawa S
Pathology; 2011 Feb; 43(2):156-60. PubMed ID: 21233678
[TBL] [Abstract][Full Text] [Related]
13. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
Vezali E; Aghemo A; Colombo M
Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
[TBL] [Abstract][Full Text] [Related]
14. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
Li LF; Shi KQ; Lin YQ; Wang LR; He JP; Braddock M; Chen YP; Zheng MH
Gene; 2014 Jul; 544(2):101-6. PubMed ID: 24793583
[TBL] [Abstract][Full Text] [Related]
16. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.
Donato MF; Fabrizi F; Fogazzi GB; Cresseri D; Passerini P; Martin P; Messa P
Int J Artif Organs; 2013 Jan; 36(1):63-8. PubMed ID: 23280083
[TBL] [Abstract][Full Text] [Related]
17. Natural history and management of hepatitis C infection after liver transplantation.
Charlton M; Wiesner R
Semin Liver Dis; 2004; 24 Suppl 2():79-88. PubMed ID: 15346250
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hepatitis C in dialysis patients.
Esforzado N; Campistol JM
Contrib Nephrol; 2012; 176():54-65. PubMed ID: 22310781
[TBL] [Abstract][Full Text] [Related]
19. Therapy of hepatitis C: from empiricism to eradication.
Pawlotsky JM
Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
[TBL] [Abstract][Full Text] [Related]
20. Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
Abdel-Wahab M; Abdel-Khalek EE; El-Gilany AH; Yassen AM; Al-Shobari M; Shiha U; Ali M; Sadani M; Salah T; Sultan AM; Elghawalby AN; Elmorshedi M; Al-Refaey AK; Abdalla U
Arab J Gastroenterol; 2017 Sep; 18(3):151-155. PubMed ID: 28958486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
